1.51
price down icon7.93%   -0.13
after-market Dopo l'orario di chiusura: 1.57 0.06 +3.97%
loading
Precedente Chiudi:
$1.64
Aprire:
$1.59
Volume 24 ore:
317.56K
Relative Volume:
2.91
Capitalizzazione di mercato:
$47.34M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-0.5432
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
-32.59%
1M Prestazione:
-71.83%
6M Prestazione:
-78.46%
1 anno Prestazione:
-77.43%
Intervallo 1D:
Value
$1.40
$1.675
Intervallo di 1 settimana:
Value
$1.40
$2.30
Portata 52W:
Value
$1.40
$11.90

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name
Nome
Acrivon Therapeutics Inc
Name
Telefono
617-207-8979
Name
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Name
Dipendente
78
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-26
Name
Ultimi documenti SEC
Name
ACRV's Discussions on Twitter

Confronta ACRV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ACRV
Acrivon Therapeutics Inc
1.51 47.34M 0 -69.00M -55.26M -2.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-31 Iniziato KeyBanc Capital Markets Overweight
2024-09-16 Aggiornamento Ladenburg Thalmann Neutral → Buy
2024-04-29 Downgrade Ladenburg Thalmann Buy → Neutral
2024-03-01 Iniziato JMP Securities Mkt Outperform
2023-12-15 Ripresa Jefferies Buy
2023-10-05 Iniziato Maxim Group Buy
2023-06-02 Iniziato Oppenheimer Outperform
2023-05-08 Iniziato BMO Capital Markets Outperform
2023-04-27 Iniziato Ladenburg Thalmann Buy
2023-04-20 Iniziato H.C. Wainwright Buy
2022-12-12 Iniziato Cowen Outperform
2022-12-12 Iniziato Jefferies Buy
2022-12-12 Iniziato Piper Sandler Overweight
Mostra tutto

Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie

pulisher
Mar 29, 2025

Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld MedTech

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains Acrivon stock with $17 target following update By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 26, 2025

Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

JMP maintains Acrivon stock with $17 target following update - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Mar 26, 2025
pulisher
Mar 25, 2025

Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Citizens JMP reiterates Acrivon stock with $17 target By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 24, 2025

Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Citizens JMP reiterates Acrivon stock with $17 target - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Acrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy Rating - TipRanks

Mar 24, 2025
pulisher
Mar 20, 2025

Acrivon Therapeutics (ACRV) to Release Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Acrivon Therapeutics to Host Corporate R&D Event to Provide - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Acrivon Unveils Next-Gen Cancer Platform: Key Updates from Leading Oncology Experts - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

Acrivon Therapeutics to Host Virtual R&D Event on March 25, 2025, Featuring Updates on ACR-368 and ACR-2316 - Nasdaq

Mar 19, 2025
pulisher
Mar 17, 2025

Acrivon Therapeutics Names Adam Levy as CFO -March 17, 2025 at 05:36 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

(ACRV) Investment Report - Stock Traders Daily

Mar 17, 2025
pulisher
Mar 16, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 33.7% in February - The AM Reporter

Mar 16, 2025
pulisher
Mar 15, 2025

Acrivon Therapeutics appoints new CFO as predecessor steps down By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 15, 2025

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 33.7% - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Acrivon Therapeutics appoints new CFO as predecessor steps down - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Acrivon Therapeutics Appoints New Chief Financial Officer - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $23.67 - Defense World

Mar 14, 2025

Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):